| |
Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability
for late stage HIV salvage therapy: A case-series experience.
Delory T, Papot E, Rioux C,
et al
J Med Virol.
2015 Dec 4.
Abstract
Successful antiretroviral therapy by using unusual
antiretroviral combinations in heavily pre-treated patients: two case
reports.
Taramasso L, Dentone C, Alessandrini A, et al
Int J STD AIDS.
2014 Oct 20.
Abstract
Analysis of intracellular human immunodeficiency virus (HIV)-1
drug resistance mutations in multi-failed HIV-1-infected patients treated with
a salvage regimen: 72-week follow-up.
Falasca F, Montagna C, Maida P, et al
Clin Microbiol Infect. 2013 Feb 26
Abstract |
How Individual Can Personalized Antiretroviral Treatment Be? Deep
Salvage in an
HIV-1-Infected Patient.
Jensen B, Esser S, Kaiser R, et al
Intervirology.
2012;55(2):167-71..
Abstract |
Safety and effectiveness of salvage therapy in HIV
patients.
Serrano Vicente MC, Navarro Aznárez H,
et al
Farm Hosp.
2011 Nov 16.
Abstract |
Antiretroviral Salvage Therapy for Multiclass Drug-Resistant
HIV-1-Infected Patients:
From Clinical Trials to Daily Clinical Practice.
Imaz A, Falcó V, Ribera E.AIDS
Rev
2011 Jul-Sep;13(3):180-93
Abstract
HIV-2 Infection, End-Stage Renal Disease and Protease Inhibitor
Intolerance:
Which Salvage Regimen?
Francisci D, Martinelli L, Weimer LE, et al
Clin Drug Investig.
2011 Feb 23.
Abstract
The prognosis of patients with dissociated
virological and immunological responses
to HAART.
Jevtović D, Salemović D, Ranin J, et al
Biomed Pharmacother.
2010 Sep 20.
Abstract |
Effective Treatment of
Deep Salvage Situation with "Non-Active HAART": Experiences with
the Expert
Advice System RADATA.
Lorenzen T, Walther I, Stoehr A, et al
Infection.
2009 Oct 13.
Abstract |
Historical resistance profile helps to predict salvage failure.
Zaccarelli M, Lorenzini P, Ceccherini-Silberstein F, et al
Antivir Ther.
2009;14(2):285-291
Abstract |
New treatment options for HIV salvage patients: An overview of second
generation PIs, NNRTIs,
integrase inhibitors and
CCR5 antagonists.
Hughes A, Barber T, Nelson M
J
Infect. 2008 Jun 13
Abstract
|
Therapy has failed: rationale and
design of the OPTIMA Trial.
Kyriakides TC, Babiker A, Singer J, et al.
Control Clin Trials. 2003 Aug;24(4):481-500.
Abstract
|
|
|
|
|
| |
Virological and immunological effects of salvage
therapy following treatment interruption
and a
shift in HIV-1 resistance genotype.
Izopet J, Souyris C, Sandres-Saune K, et al
Med Virol 2002 Nov;68(3):305-10
Abstract |
|
|
|
|
| |
Salvage antiretroviral therapy in HIV infection.
Walmsley SL, Loutfy MR.
Expert Opin
Pharmacother 2002 Feb;3(2):81-90
Abstract
|
|
| |
Impact of HIV Type 1 Drug Resistance Mutations and Phenotypic Resistance Profile
on Virologic
Response to Salvage Therapy.
Ross L, Liao Q, Gao H, Pham S, et al.
AIDS Res Hum Retroviruses 2001 Oct;17(15):1379-85
Abstract
|
|
|
Journal Papers, Abstracts, and
Commentaries
Conference Reports, Abstracts, and
Posters
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader